Garnet Equity Capital Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

Garnet Equity Capital Holdings’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,000	Closed	-$1.44M	–	39
2023 Q2	$1.44M	Hold	2,000	–	–	0.51%	23
2023 Q1	$1.64M	Buy	+2,000	New	+$1.51M	0.82%	15
2021 Q3	–	Sell	-8,000	Closed	-$4.47M	–	54
2021 Q2	$4.47M	Hold	8,000	–	–	0.69%	19
2021 Q1	$3.79M	Hold	8,000	–	–	0.85%	22
2020 Q4	$3.87M	Hold	8,000	–	–	1.14%	20
2020 Q3	$4.48M	Hold	8,000	–	–	0.92%	14
2020 Q2	$4.99M	Buy	+8,000	New	+$4.54M	0.99%	6

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Garnet Equity Capital Holdings's REGN Position: Q3 2023 in Review

Garnet Equity Capital Holdings sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 2,000 shares — an estimated $1.44M sold.

Garnet Equity Capital Holdings first reported a position in REGN in Q2 2020 and held it in 7 quarters. The position peaked at $4.99M in Q2 2020. 1,178 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

Garnet Equity Capital Holdings reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Garnet Equity Capital Holdings sold 2,000 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $1.44M.
Garnet Equity Capital Holdings first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Garnet Equity Capital Holdings's Regeneron Pharmaceuticals position peaked at $4.99M in Q2 2020.
1,178 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Garnet Equity Capital Holdings's 13F filing for Q3 2023, filed 13 Nov 2023.